D-0570-2023 Class III Terminated
FDA drug recall D-0570-2023 was initiated by The Harvard Drug Group on Apr 24, 2023 and is designated Class III. Reason for recall: Product mixup: one foreign tablet found in product. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 3984 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- May 17, 2023
- Initiation Date
- Apr 24, 2023
- Termination Date
- Apr 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 3984 cartons
Product description
Gabapentin Tablets, USP 600 mg, packaged in Cartons of 100 tablets (10 tablets per blister pack x 10), Rx Only, Distributed by: Aurobindo Pharma USA, Inc. East Windsor, NJ 08520 Distributed by: Major Pharmaceuticals 17177 N Laurel Park Dr., Suite 233 Livonia, MI 48152 USA, NDC 0904-6823-61
Reason for recall
Product mixup: one foreign tablet found in product.
Distribution pattern
USA Nationwide
Code information
Lot: T04468, Exp 10/2024
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0570-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026